SNP (Single Nucleotide Polymorphism) marker for detecting RHD blood group mutation site and application
By detecting specific SNP markers in the second exon region of the RHD gene, the problem of difficulty in accurately detecting RHD blood type mutations in the prior art is solved, and kits and systems for detection are provided to achieve accurate accuracy for Rh negative individuals Guarantees for identification and blood transfusion safety.
Patent Information
- Application Number
- CN202411419662.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing technologies are difficult to accurately detect RHD blood type mutation sites, which leads to patients with Rh-negative blood type facing the risk of hemolytic reactions and neonatal hemolytic disease during blood transfusion and pregnancy and childbirth, and lacks effective genetic diagnosis pathways.
PCR amplification and sequencing using SNP markers and specific primer pairs (RHD-2F and RHD-2R) were used to detect specific mutations in the second exon region of the RHD gene in the erythrocytes (C→T and G insertions) to determine the RHD blood type , a kit and a detection system are provided for detection.
The accurate diagnosis of RHD blood type is achieved, the production of irregular antibodies during blood transfusion and pregnancy and childbirth is reduced, the occurrence of neonatal hemolytic diseases is reduced, and the accurate identification and blood transfusion safety of Rh-negative individuals are ensured.
Smart Images

Figure CN118932038A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of gene diagnosis products, and in particular to a SNP marker for detecting RHD blood type mutation sites and its application. Background Art
[0002] The RHD blood group system, also known as the Rh blood group system, is a blood group system used to classify human red blood cells. The most famous antigen in the Rh blood group system is the D antigen, so the Rh blood group commonly referred to refers to the RHD blood group. The Rh blood group system was discovered by scientists Landsteiner and Wiener in 1940. Rh is the abbreviation of Rhesus (rhesus monkey) because this blood group system was first discovered in rhesus monkeys. The Rh blood group system contains more than 50 different antigens, among which the D antigen is the most important. Depending on the presence or absence of the D antigen, the Rh blood type is divided into Rh positive (RHD positive) and Rh negative (RHD negative). Inheritance of Rh blood type: Rh blood type is inherited from parents to children. If both parents are Rh positive, the children may also be Rh negative, but this is rare. If one parent is Rh negative, the children may also be Rh negative.
[0003] Rh-negative blood type is relatively rare in my country. Because its preciousness is similar to that of pandas, it is called "panda blood". In my country, the proportion of Rh-negative blood type is about 0.2%-0.5%, which is much lower than that of Rh-positive blood type. During blood transfusion, if the recipient is Rh-negative and Rh-positive blood is transfused, hemolytic reaction may occur. Therefore, for patients with Rh-negative blood type, Rh-negative blood is preferred for transfusion. If the pregnant woman is Rh-negative and the fetus is Rh-positive, the immune system of the pregnant woman may produce antibodies to attack the red blood cells of the fetus, leading to hemolytic disease of the newborn. Therefore, Rh-negative pregnant women need to pay special attention during pregnancy and, if necessary, receive anti-D immunoglobulin injections to prevent hemolytic disease of the newborn.
[0004] In short, the RHD blood group system is a classification method for human red blood cells. Panda blood (Rh-negative blood type) has attracted much attention due to its rarity and special nature during blood transfusion. During medical treatment and pregnancy, special measures need to be taken for patients and pregnant women with Rh-negative blood type.
[0005] Based on this, the present invention proposes a SNP marker for detecting RHD blood type mutation sites and its application. Summary of the invention
[0006] The present invention provides a SNP marker for detecting RHD blood type mutation sites and its application, which can accurately confirm the RHD mutation blood type gene of red blood cells, thereby making up for the deficiencies of the prior art.
[0007] According to one aspect of the present disclosure, a SNP marker for detecting RHD blood type mutation sites is provided. The SNP marker is the second exon of the RHD gene coding region encoding the red blood cell surface D antigen. The 208th base from the start codon mutates from C to T; and G is inserted between the 210th and 211th bases.
[0008] A primer pair is provided, which is used for performing RHD blood type gene detection to detect whether the SNP marker exists, and the sequence information of the primers is as follows: Primer RHD-2F: 5′-CCCTCGTCCTTCTCGCCAT-3′; Primer RHD-2R: 5'-AGGATGCCCAGTTAATTTGAATTT-3'.
[0009] Provided is an application of a primer pair, wherein the primer pair is the above primer pair, and the primer pair is used in preparing a product for detecting red blood cell RHD variant blood type.
[0010] In a possible implementation, the product is a PCR amplification reaction kit.
[0011] Provided is a kit for detecting RHD blood type, wherein the kit comprises a primer pair for detecting the SNP marker.
[0012] Provided is an application of a SNP marker, the SNP marker being the above-mentioned SNP marker, and the application being an application of the SNP marker in detecting RHD blood type mutations in red blood cells, comprising: using the primers to perform PCR amplification on a blood sample DNA to be detected to obtain an amplification product; sequencing the amplification product to obtain a sequencing result; and performing genotype analysis based on the sequencing result to determine whether the sample to be detected contains the SNP marker.
[0013] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides an effective way to diagnose RHD blood type genes by detecting and screening the obtained SNP sites. The application results show that the SNP sites and detection primers provided by the present invention can be effectively used for rapid detection of RHD genes in transfusion patients and blood donors in blood stations.
[0014] By using molecular biological methods, an RHD gene detection system has been established and applied in clinical blood transfusion work, which helps to accurately detect RHD-negative individuals, reduce the production of irregular antibodies in blood recipients, prevent and monitor irregular antibodies before delivery, and reduce the occurrence of neonatal hemolytic disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1Shown is the direct sequencing diagram of the RHD gene in a normal individual.
[0016] Figure 2 Shown is the direct sequencing map of the proband's RHD gene.
[0017] Figure 3 Direct sequencing of another patient in the proband's family who carried the mutated gene (carrying the RHD positive gene and the RHD mutated gene).
[0018] Figure 4 Cloning sequencing map of another person in the proband's family who carries the mutant gene (carrying the RHD mutant gene). DETAILED DESCRIPTION
[0019] Various exemplary embodiments, features and aspects of the present disclosure will be described in detail below with reference to the accompanying drawings. The same reference numerals in the accompanying drawings represent elements with the same or similar functions. Although various aspects of the embodiments are shown in the accompanying drawings, the drawings are not necessarily drawn to scale unless otherwise specified.
[0020] The word “exemplary” is used exclusively herein to mean “serving as an example, example, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.
[0021] In addition, in order to better illustrate the present disclosure, numerous specific details are given in the following specific embodiments. It should be understood by those skilled in the art that the present disclosure can also be implemented without certain specific details. In some examples, methods, means, components and circuits well known to those skilled in the art are not described in detail in order to highlight the main purpose of the present disclosure.
[0022] from Figure 2 It can be seen that the proband carries one RHD mutant gene and one RHD complete deletion gene.
[0023] Figure 3 It can be seen from the direct sequencing results of another member of the proband's family who carries the mutant gene (such as the proband's mother) Figure 3 It can be seen that this member carries the RHD positive gene and the RHD mutant gene.
[0024] Figure 4 The clone sequence map of a person in the family carrying the mutant gene (e.g., the proband's mother) can be seen in the figure. Figure 4 It can be seen that this member carries the same RHD mutation gene as the proband.
[0025] RHD gene sequencing was performed on 309 individuals who were RHD negative or variant by serological testing, and a new SNP mutation leading to RHD variant was found. This variant individual fully expressed the entire RHD gene, which led to the present invention.
[0026] The RH gene is located in the chromosome 1p34.3-1p36.1 region and can be transcribed into 2837bp of mRNA (NCBI accession number is NM_016124.4), which is finally translated into a protein composed of 417 amino acids. It is composed of the RHD gene (encoding the RHD antigen) and the RHCE gene (encoding the RHC, c, E and e antigens) arranged in close series. The RHD gene and the RHCE gene are highly homologous in structure, both consisting of 10 exons and 9 introns, of which the 8th exon of the two is exactly the same, and the biggest difference is exon 3, 4, 5, 7, 9 and intron 4. Therefore, the RHD gene detection system is established by molecular biology and applied to clinical blood transfusion work, which is helpful for the accurate detection of RHD-negative individuals, helps to reduce the production of irregular antibodies in blood recipients, helps to prevent and monitor irregular antibodies before delivery, and helps to reduce the occurrence of neonatal hemolytic disease.
[0027] SNP (single nucleotide polymorphism) refers to the DNA sequence polymorphism caused by the variation of a single nucleotide at the genome level. The polymorphism exhibited by SNP only involves the variation of a single base, which is manifested by transition, transversion, insertion and deletion.
[0028] The present invention is described in detail below with reference to the embodiments.
[0029] Example 1: Screening of SNP markers 1. Extraction of peripheral blood genomic DNA: In compliance with relevant national policies and regulations and with the consent of the sampling subjects, 2-5 mL of RHD-negative or variant peripheral venous blood was drawn and placed in EDTA anticoagulant tubes and frozen at -80°C for later use; after the frozen EDTA anticoagulant blood was thawed at room temperature, 500 μL was taken and placed in a centrifuge tube, and an equal volume of TE (a commonly used buffer solution composed of Tris (a trishydroxymethylaminomethane) and EDTA (an ethylenediaminetetraacetic acid), where Tris serves as a pH buffer and EDTA serves as a metal ion chelator) was added, with the pH of TE being 8.0. Mix well, centrifuge at 4°C, 10,000 rpm for 10 minutes, and discard the supernatant.
[0030] Add 180 μL of TE, 20 μL of SDS (10%) (SDS is the abbreviation of sodium dodecyl sulfate in biology. SDS is an anionic detergent. As a denaturant and solubility aid, it can break the hydrogen bonds within and between molecules, unfold the molecules, and thus destroy the secondary and tertiary structures of protein molecules), and 8 μL of proteinase K (10 mg / ml), mix well, and place in a 37°C water bath overnight. Remove the sample from the water bath and centrifuge it to precipitate the sample. Add an equal volume of Tris-saturated phenol (about 300 μL) to the reaction tube, mix well, centrifuge at 10,000 rpm at room temperature for 10 minutes, and aspirate the supernatant (about 300 μL) into a new centrifuge tube. Repeat the phenol extraction once and aspirate the supernatant into a new centrifuge tube.
[0031] Add an equal volume of Tris-saturated phenol:chloroform mixture (150 μL each of phenol and chloroform), mix well, centrifuge at 10,000 rpm for 10 minutes at room temperature, and transfer the supernatant to a new centrifuge tube.
[0032] Add an equal volume of Tris-saturated phenol:chloroform:isoamyl alcohol mixture (100 μL each of phenol, chloroform, and isoamyl alcohol), mix well, centrifuge at 10,000 rpm for 10 minutes at room temperature, and transfer the supernatant to a new centrifuge tube.
[0033] Add 1 / 10 volume of 3 mol / L, pH 5.2 sodium acetate (about 30 μL) and 2 times volume of pre-cooled 100% ethanol (600 μL), mix gently, and white flocculent precipitate can be seen. Centrifuge at room temperature at 10,000 rpm for 10 minutes to precipitate the DNA at the bottom of the tube, and discard the supernatant.
[0034] Add 70% ethanol to the DNA precipitate, rinse once, centrifuge at 7000 rpm at room temperature for 5 minutes, discard the supernatant, and place at room temperature to evaporate the remaining ethanol. Finally, add 50 μL TE (pH 8.0) and dissolve the DNA at 4°C overnight.
[0035] The extracted DNA was subjected to agarose gel electrophoresis, and the purity and concentration of the DNA were detected by ultraviolet spectrophotometer at 260nm and 280nm.
[0036] 2. Perform PCR amplification and sequencing of genomic DNA to search for mutations in the proband's RHD gene PCR amplification of target fragments: reaction conditions and reaction system: (1) PCR reaction conditions: 95°C for 5 min; 95°C for 30 s, 58°C for 30 s, 72°C for 60 s, 35 cycles; 72°C for 5 min.
[0037] (2) Reaction system: (Onelambda Fast startTaq polymerase) 2×mix buffer 10µl RHD-2F primer (2.5µM) 2µl RHD-2R primer (2.5µM) 2µl Fast startTaq polymerase 1µl (1.25U) Genomic DNA template (50ng / ul) 1µl dH2O 4µl Total 20µl Among them, 2×mix buffer is the premixed reaction solution in the PCR reaction, Fast startTaq polymerase is the fast start polymerase, and dH2O is single distilled water.
[0038] The reaction system is used to perform amplification reaction between the genomic DNA template of each RHD-negative or D-variant individual and the RHD primer.
[0039] Direct sequencing of PCR products: The above PCR products were sequenced using the conventional Sanger sequencing method, RHD-2F: 5'-CCCTCGTCCTTCTCGCCAT-3'. The proband carried a RHD mutant gene and a RHD complete deletion gene. Two mutations were found in the second exon of the RHD gene in the RHD variant individual. A C>T mutation occurred at the 208th base from the start codon; a G was inserted between the 210th and 211th bases ( Figure 2 ). This resulted in the conversion of the 70th amino acid from arginine to tryptophan; subsequently, the insertion of G between the 2010th and 211th bases caused a frameshift mutation, which affected the expression of the variant RHD gene. Although the proband expressed a complete RHD gene, the serological phenotype was RHD-negative.
[0040] The results of multiple sequencing showed that this mutation site was not introduced due to amplification or sequencing errors, but should be a new mutation. This mutation does not exist in the following four databases: single nucleotide polymorphism database (ftp: / / ftp.ncbi.nih.gov / snp / database / ), 1000 Genomes Project (ftp: / / ftp-trace.ncbi.nih.gov / 1000genomes / ftp / ), Hapmap8 database (http: / / hapmap.ncbi.nlm.nih.gov / ), and Yanhuang database (http: / / yh.genomics.org.cn / ), indicating that this mutation is very rare. This mutation causes a change in the conformation of the D antigen protein, thus leading to the RHD variant. However, the mutation screening of this site in the peripheral blood genomic DNA samples of 309 RHD-positive individuals did not find this mutation.
[0041] The above analysis proves that this method can accurately determine the RHD gene, thereby more accurately determining the RHD blood type of the person being tested, which is of great significance for formulating blood transfusion policies for patients.
[0042] Example 2: Genetic verification of family members of a proband with a SNP mutation 1. Extraction of peripheral blood genomic DNA: In accordance with relevant national policies and regulations and with the consent of the sampling subjects, 2-5 mL of peripheral venous blood was drawn from the proband's family members, placed in EDTA anticoagulant tubes, and frozen at -80°C for later use. After the frozen EDTA anticoagulant blood was thawed at room temperature, 500 μL was taken out and placed in a centrifuge tube, and an equal volume of TE (pH 8.0) was added. The mixture was mixed, and centrifuged at 4°C, 10,000 rpm for 10 min, and the supernatant was discarded.
[0043] Add 180 μL of TE, 20 μL of SDS (10%), and 8 μL of proteinase K (10 mg / ml), mix well, and place in a 37°C water bath overnight. Remove the sample from the water bath and centrifuge it to precipitate the sample. Add an equal volume of Tris-saturated phenol (about 300 μL) to the reaction tube, mix well, centrifuge at 10,000 rpm for 10 minutes at room temperature, and aspirate the supernatant (about 300 μL) into a new centrifuge tube. Repeat the phenol extraction once and aspirate the supernatant into a new centrifuge tube.
[0044] Add an equal volume of Tris-saturated phenol:chloroform mixture (150 μL each of phenol and chloroform), mix well, centrifuge at 10,000 rpm for 10 minutes at room temperature, and transfer the supernatant to a new centrifuge tube.
[0045] Add an equal volume of Tris-saturated phenol:chloroform:isoamyl alcohol mixture (100 μL each of phenol, chloroform, and isoamyl alcohol), mix well, centrifuge at 10,000 rpm for 10 minutes at room temperature, and transfer the supernatant to a new centrifuge tube.
[0046] Add 1 / 10 volume of 3 mol / L, pH 5.2 sodium acetate (about 30 μL) and 2 times volume of pre-cooled 100% ethanol, mix gently, and white flocculent precipitate will be visible. Centrifuge at room temperature at 10,000 rpm for 10 minutes to precipitate the DNA at the bottom of the tube, and discard the supernatant.
[0047] Add 70% ethanol to the DNA precipitate, rinse once, centrifuge at 7000 rpm at room temperature for 5 minutes, discard the supernatant, let it stand at room temperature to evaporate the remaining ethanol, and finally add 50 μL of TE (pH 8.0) and dissolve the DNA at 4°C overnight.
[0048] The extracted DNA was subjected to agarose gel electrophoresis, and the purity and concentration of the DNA were detected by ultraviolet spectrophotometer at 260nm and 280nm.
[0049] 2. Perform PCR amplification and sequencing of genomic DNA to search for mutations in the second exon of the RHD gene in the proband's parents PCR amplification of target fragments: reaction conditions and reaction system: (1) PCR reaction conditions: 95°C for 5 min; 95°C for 30 s, 58°C for 30 s, 72°C for 60 s, 35 cycles; 72°C for 5 min.
[0050] (2) Reaction system: (Onelambda Fast start Taq polymerase) 2×mix buffer 10µl RHD-2F primer (2.5µM) 2µl RHD-2R primer (2.5µM) 2µl Fast startTaq polymerase 1µl (1.25U) Genomic DNA template (50ng / ul) 1µl dH2O 4µl Total 20µl The reaction system was used to carry out amplification reactions of genomic DNA templates and amplification primers of the proband's family members.
[0051] PCR product sequencing: The PCR products were sequenced using conventional Sanger sequencing. The mother of the proband had a normal RHD positive phenotype and carried a mutant gene, which was manifested by a CT heterozygous mutation at the 208th base from the start codon; a heterozygous peak caused by the insertion of G between the 210th and 211th bases ( Figure 3 shown).
[0052] The mutation is not present in the following four databases: Single Nucleotide Polymorphism Database (ftp: / / ftp.ncbi.nih.gov / snp / database / ), 1000 Genomes Project (ftp: / / ftp-trace.ncbi.nih.gov / 1000genomes / ftp / ), Hapmap8 Database (http: / / hapmap.ncbi.nlm.nih.gov / ), and Yanhuang Database (http: / / yh.genomics.org.cn / ), indicating that the mutation is very rare.
[0053] 3. Perform haplotype sequencing on the second exon of the RHD gene of the proband's family members to determine the mutation site of the RHD gene of the proband's family members Primer for PCR amplification of target fragment: RHD-2F: 5′-CCCTCGTCCTTCTCGCCAT-3′; RHD -2R:5'-AGGATGCCCAGTTAATTTGAATTT-3'.
[0054] PCR amplification primers may also be selected from other primer pairs that can amplify the above-mentioned SNP sites.
[0055] Reaction conditions and reaction system for PCR amplification of target fragments: (1) PCR reaction conditions: pre-denaturation at 95°C for 5 min; 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 50 s; extension at 72°C for 5 min, and incubation of the amplified product at 10°C.
[0056] (2) Reaction system: (TAKARA LA-Taq polymerase) 2×mix buffer 10µl RHD-2F primer (2.5µM) 2µl RHD-2R primer (2.5µM) 2µl Fast startTaq polymerase 1µl (1.25U) Genomic DNA template (50ng / ul) 1µl dH2O 4µl Total 20µl This reaction system was used to perform amplification reaction on the genomic DNA template of the family members and the amplification primers designed by the inventors. The PCR product was cloned into the T vector, and multiple colonies were picked for haplotype sequence determination. The haplotype sequencing primers provided in the kit were used to determine the haplotype sequence of the sample ( Figure 4 ).
[0057] This mutation is a newly discovered mutation. It does not exist in the following four databases: Single Nucleotide Polymorphism Database (ftp: / / ftp.ncbi.nih.gov / snp / database / ), 1000 Genomes Project (ftp: / / ftp-trace.ncbi.nih.gov / 1000genomes / ftp / ), Hapmap8 Database (http: / / hapmap.ncbi.nlm.nih.gov / ), and Yanhuang Database (http: / / yh.genomics.org.cn / ), indicating that this mutation is very rare.
[0058] The above experimental results show that the SNP mutation site can accurately determine the RHD blood type mutation gene of the subject, which is of great significance for formulating blood transfusion policies for patients.
[0059] Combination Figure 1-Figure 4 The above-mentioned embodiments 1 and 2 are described in detail: Figure 1 Shown is the direct sequencing diagram of the RHD gene in a normal individual. Figure 2 The direct sequencing of the proband's RHD gene is shown. Figure 2 You can see the Figure 1 In comparison, the proband had two mutations (a mutation occurred at the 208th base from the start codon, from C to T; a G was inserted between the 210th and 211th bases). In order to find out whether this mutation came from the father or the mother, the parents were sequenced and it was found that both mutations of the proband came from his mother. What we see is Figure 3 The results are from the patient's mother. However, the direct sequencing graphs of the mother and the patient are not exactly the same. Figure 2 The two mutations shown here also have another RH gene, so the mother's Figure 3 After position 211, there are double peaks. (The patient does not have double peaks because one of his RHD genes is completely deleted.) Therefore, in order to clarify the gene sequence of the double peak position of the proband's mother, the PCR amplification product was sequenced by monoclonal sequencing, that is, the two RH genes present were measured separately, and it was found that one was normal and the other was Figure 4 The mutant sequence shown. Figure 4 and Figure 2 The mutation sites are the same, which means that the patient's two mutations were inherited from his mother.
[0060] The flow chart and block diagram in the accompanying drawings show the possible architecture, function and operation of the system, method and computer program product according to multiple embodiments of the present disclosure. In this regard, each square box in the flow chart or block diagram can represent a part of a module, program segment or instruction, and a part of the module, program segment or instruction includes one or more executable instructions for realizing the specified logical function. In some alternative implementations, the function marked in the square box can also occur in a sequence different from that marked in the accompanying drawings. For example, two continuous square boxes can actually be executed substantially in parallel, and they can sometimes be executed in reverse order, depending on the functions involved. It should also be noted that each square box in the block diagram and / or flow chart, and the combination of the square boxes in the block diagram and / or flow chart can be implemented with a dedicated hardware-based system that performs the specified function or action, or can be implemented with a combination of special hardware and computer instructions.
[0061] The embodiments of the present disclosure have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and changes will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.
Claims
1. A SNP marker for detecting RHD blood type mutation sites, characterized in that: The SNP marker is the second exon of the coding region of the RHD gene encoding the D antigen on the red blood cell surface. A mutation occurred at the 208th base from the start codon, from C to T; and a G was inserted between the 210th and 211th bases.
2. A primer pair, characterized in that: The primer pair is used for RHD blood type gene detection to detect whether the SNP marker in claim 1 exists, and the sequence information of the primers is as follows: Primer RHD-2F: 5′-CCCTCGTCCTTCTCGCCAT-3′; Primer RHD-2R: 5'-AGGATGCCCAGTTAATTTGAATTT-3'.
3. An application of a primer pair, characterized in that: The primer pair is the primer pair in claim 2, and the primer pair is used in the preparation of a product for detecting RHD variant blood type of red blood cells.
4. The use of the primer pair according to claim 3, characterized in that: The product is a PCR amplification reaction kit.
5. A kit for detecting RHD blood type, characterized in that: The kit comprises a primer pair for detecting the SNP marker according to claim 1.
6. An application of a SNP marker, characterized in that: The SNP marker is the SNP marker in claim 1, and the application is the application of the SNP marker in detecting the RHD blood type mutation of red blood cells, including: using the primers in claim 2 to perform PCR amplification on the blood sample DNA to be detected to obtain an amplification product; sequencing the amplification product to obtain a sequencing result; performing genotype analysis based on the sequencing result to determine whether the SNP marker in claim 1 exists in the sample to be tested.
Citation Information
Patent Citations
SNP marker for detecting RhD negative phenotype
CN106834287A
Primer group for detecting RhD negative blood type and application thereof
CN106967808A
Discrimination of blood type variants
US20140255923A1
Fetal RHD blood type detection kit and use thereof
WO2020218499A1
